You were invited to our Q4/2024 Townhall, where we explored our future organization based on what has been agreed upon until then. Updates from our Leadership Team included insights from the PH Strategy Summit, which did initiate discussions on our financials and the strategic mid- and long-term outcomes for Pharma. Additionally, we reflected on the results of the Ownership Pulse (formerly known as Employee Voice), discussed further considerations, and allocated time for a Q&A session. This token serves as appreciation for and proof of your participation. POAP dropped for Bayer DT&IT Pharma Design by stefankai with Canva POAP Terms & Conditions: https://bayer.com/poap Bayer IT POAP Collection: https://collections.poap.xyz/bayer-it/

Another DSO Open MIC session is in the books! Whether you have attended the morning or afternoon session, without a doubt you have contributed significantly to the success of today's event. These sessions are a space for open exchanges about ongoing topics around DSO and an opportunity to share, ask questions, provide feedback, or just listen. Everyone is invited to attend, participation is voluntary, and the sessions will not be recorded. Bayer terms & conditions apply: https://www.bayer.com/en/poap-tc

Rare diseases are defined by their low prevalence in the population, leading to challenges in diagnosis, research, and treatment. Definitions vary; in the US, a disease is rare if it affects fewer than 1:1,500 individuals, Europe 1:2,000, Japan 1:2,500. There are some 7,000 rare diseases, impacting around 6-8% of the world at some point, some 300 million currently. They are incredibly diverse, ranging from genetic disorders to rare cancers, and can be chronic, progressive, debilitating, and often life-threatening. Some well-known rare diseases include cystic fibrosis, Duchenne muscular dystrophy, and Huntington's disease, each with their own unique symptoms, treatment challenges, and research needs. Rare diseases are closely related to orphan diseases, a term that originally referred to diseases neglected by drug developers due to the small market potential. However, the terms are now often used interchangeably. Legislation such as the Orphan Drug Act of 1983 in the U.S. has incentivized pharmaceutical companies to develop treatments for rare (orphan) diseases, offering benefits like tax credits and exclusive marketing rights. The rarity and diversity of these diseases pose significant hurdles for research and clinical trials, Raising awareness and support for those affected are crucial for research funding to develop diagnostics, treatments, and hopefully cures. https://en.wikipedia.org/wiki/Rare_disease Art+Text supported by ChatGPT